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mode contributes, but does not resolve, problems of high
volume hemodiafiltration. The focus on high blood flow
should not be lost; and (4) the application of the “alter-
nate” mode of prescription of CRRT, which hopefully
will facilitate the cooperation with the intensivists.
The major concern is treatment dose. When accepting
the data of Ronco [2], this patient is undertreated: total
small molecular clearance, 37 mL/min versus 48 mL/min.
Contribution of convective clearance, 25 mL/min versus
48 mL/min.
Are there any hints indicating that smaller treatment
doses than those of Ronco might be adequate?
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Herb-associated
carcinogenicity and chronic
renal failure in Asian patients
with kidney cancer and
hypertension
To the Editor: With great interest, we have read the
paper in a recent issue of Kidney International by Choi
et al [1] that hypertension is an independent risk factor of
kidney cancer mortality. However, we wonder whether
all the reported deaths of “kidney cancer” were defi-
nitely pathology-proven renal cell carcinomas (RCCs) or
if some of them were cancers of the renal pelvis [i.e., tran-
sitional cell carcinomas (TCCs)] in nature. Though RCCs
account for about 80% to 85% of all primary renal neo-
plasms, TCCs arising from the renal pelvis are the next
most common and account for 7%∼8% of primary renal
neoplasms [2]. Further, considering the high frequency of
using herbs as alternative medicine for chronic diseases
(e.g., hypertension, heart disease, diabetes, asthma, etc.)
in Asian aged people, the risk of herb-associated carcino-
genicity (e.g., aristolochic acid-associated uroepithelial
cancers in human [3], TCCs, and RCCs in rats) should be
further investigated. Meanwhile, the patients’ renal func-
tion should also be analyzed because chronic renal failure
(e.g., tuberous sclerosis, autosomal-dominant polycystic
kidney disease, and von Hippel-Lindau disease) or end-
stage renal disease (e.g., RCCs develop in 3.8% to 4.2%
of ESRD patients with acquired polycystic kidney dis-
ease), per se, is somewhat associated with RCCs [4], and
it may be the result of herb nephropathy in patients with
significant history of herb use. Ideally, the renal function
and pathology of these 92 deaths from “kidney cancer”
should be reviewed to exclude the aforementioned con-
founding factors and search the possible evidence of herb
nephropathy correlated to TCCs or RCCs.
MING-YU LAI and WU-CHANG YANG
Taipei, Taiwan
Correspondence to Ming-Yu Lai, M.D., Division of Nephrology,
Taipei Veterans General Hospital, No. 201, Sec. 2, Shih-Pai Road, Taipei,
Taiwan 112.
E-mail: mylai@vghtpe.gov.tw
REFERENCES
1. CHOI MY, JEE SH, SULL JW, et al: The effect of hypertension on the
risk for kidney cancer in Korean men. Kidney Int 67:647–652, 2005
2. JONASCH E, GEROGE DJ: Renal neoplasia, in Brenner & Rector’s The
Kidney, 7th ed. (vol 2), edited by Brenner BM, Philadelphia, Elsevier,
Inc., 2004, pp 1896–1923
3. NORTIER JL, MARTINEZ MC, SCHMEISER HH, et al: Urothelial car-
cinoma associated with the use of a Chinese herb (Aristolochia
fangchi). N Engl J Med 342:1686–1692, 2000
4. DENTON MD, MAGEE CC, OVUWORIE C, et al: Prevalence of renal cell
carcinoma in patients with ESRD pre-transplantation: A pathologic
analysis. Kidney Int 61:2201–2209, 2002
Dehydration versus volume
depletion
To the Editor: In his recent Nephrology Forum, Dr.
Friedman [1] makes a number of interesting and cogent
observations regarding enteral and parenteral fluid and
electrolyte therapy in infants and children. However, I
believe discussions of fluid and electrolyte disorders, and
their treatments, become much clearer and more easily
understood when terms such as “hydration,” “dehydra-
tion,” “volume depletion,” and “volume expansion” are
used in a more exacting and restricted fashion. As Menge
et al [2] describe in their article, “hydration” is best used
to define the ratio between total body solute and total
